Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases
- PMID: 1909635
- DOI: 10.1111/j.1365-2362.1991.tb01375.x
Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases
Abstract
Analyses of the urinary concentration relative to creatinine of the collagen crosslinks, pyridinoline (Pyd) and deoxy-pyridinoline (Dpd) were made in 47 patients with metabolic bone diseases to assess the validity of these assays as indicators of bone resorption. The mean values for patients with Paget's disease of bone, primary hyperparathyroidism and osteomalacia were significantly higher (P less than 0.001) than those for age-matched healthy individuals. During treatment of Paget's disease with bisphosphonates, there was a steady decline in the urinary concentration of the crosslinks to the normal range; this change occurred earlier than for serum alkaline phosphatase. There were significant correlations (P less than 0.01) between the concentrations of both crosslinks and the corresponding values for hydroxyproline. At lower crosslink concentrations, however, these relationships were less marked due to large variations in hydroxyproline values. The results show that measurements of urinary Pyd and Dpd provide clinically applicable indices of bone resorption that are more specific than other markers.
Similar articles
-
Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.Bone Miner. 1990 Jan;8(1):87-96. doi: 10.1016/0169-6009(91)90143-n. Bone Miner. 1990. PMID: 2106358
-
Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?Bone Miner. 1993 Jul;22(1):1-8. doi: 10.1016/s0169-6009(08)80076-1. Bone Miner. 1993. PMID: 8219934
-
Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.J Bone Miner Res. 1994 Oct;9(10):1643-9. doi: 10.1002/jbmr.5650091019. J Bone Miner Res. 1994. PMID: 7817812 Clinical Trial.
-
Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview.Chin Med J (Engl). 2004 Feb;117(2):291-5. Chin Med J (Engl). 2004. PMID: 14975218 Review.
-
[Usefulness of bone remodelling biochemical markers in the diagnosis and follow-up of Paget's bone disease, primary hyperparathyroidism, tumor hypercalcemia, and postmenopausal osteoporosis. II. Bone resorption markers].An Med Interna. 1990 Oct;7(10):534-8. An Med Interna. 1990. PMID: 2104101 Review. Spanish.
Cited by
-
Corticosteroid-sparing options in the treatment of childhood asthma.Drugs. 2000;59 Suppl 1:15-22; discussion 43-5. doi: 10.2165/00003495-200059001-00003. Drugs. 2000. PMID: 10741878 Review.
-
Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.Front Oncol. 2021 Oct 14;11:692788. doi: 10.3389/fonc.2021.692788. eCollection 2021. Front Oncol. 2021. PMID: 34722241 Free PMC article. Review.
-
Urinary free deoxypyridinoline levels during childhood.J Endocrinol Invest. 1998 May;21(5):318-22. doi: 10.1007/BF03350335. J Endocrinol Invest. 1998. PMID: 9648054 Clinical Trial.
-
The effect of menopause on biochemical markers and ultrasound densitometry in healthy females.Calcif Tissue Int. 1994 Dec;55(6):420-5. doi: 10.1007/BF00298555. Calcif Tissue Int. 1994. PMID: 7895180 Clinical Trial.
-
Pyridinium cross-links in heritable disorders of collagen.Am J Hum Genet. 1995 Dec;57(6):1508-10. Am J Hum Genet. 1995. PMID: 8533784 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources